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Protocol
AbstrACt
Introduction Antibiotic resistance endangers effective 
prevention and treatment of infections, and places 
significant burden on patients, families, communities and 
healthcare systems. Low-income and middle-income 
countries (LMICs) are especially vulnerable to antibiotic 
resistance, owing to high infectious disease burden, 
and limited resources for treatment. High prevalence of 
antibiotic prescription and use due to lack of provider’s 
knowledge, prescriber’s habits and perceived patient 
needs further exacerbate the situation. Interventions 
implemented to address the inappropriate prescription 
and use of antibiotics in LMICs must address different 
determinants of antibiotic resistance through sustainable 
and scalable interventions. The aim of this protocol is to 
provide a comprehensive overview of the methods that 
will be used to identify and appraise evidence on the 
effectiveness and cost-effectiveness of behaviour change 
interventions implemented in LMICs to improve the 
prescription and use of antibiotics.
Methods and analysis Two databases (Web of Science 
and PubMed) will be searched based on a strategy 
developed in consultation with an essential medicines 
and health systems researcher. Additional studies will 
be identified using the same search strategy in Google 
Scholar. To be included, a study must describe a behaviour 
change intervention and use an experimental design to 
estimate effectiveness and/or cost-effectiveness in an 
LMIC. Following systematic screening of titles, abstracts 
and keywords, and full-text appraisal, data will be 
extracted using a customised extraction form. Studies will 
be categorised by type of behaviour change intervention 
and experimental design. A meta-analysis or narrative 
synthesis will be conducted as appropriate, along with 
an appraisal of quality of studies using the Grading 
of Recommendation, Assessment, Development and 
Evaluation (GRADE) checklist.
Ethics and dissemination No individual patient data are 
used, so ethical approval is not required. The systematic 
review will be disseminated in a peer-reviewed journal and 
presented at a relevant international conference.
PrOsPErO registration number CRD42017075596
IntrOduCtIOn
Antibiotic resistance (ABR) is recognised 
as one of the greatest threats to human 
health.1 2 It endangers the effective preven-
tion and treatment of a range of infections 
as it often results in prolonged illness, and 
consequently, patients remain infectious for 
a longer time.3 There is also an increased 
risk of spreading resistant micro-organisms 
to others.4 5 Owing to resistance to first-line 
drugs, alternative and more expensive and 
lengthy treatment procedures must be used, 
placing a strain on the healthcare system.6–8 
This adds to the burden on individuals, 
their families and communities who bear 
higher direct and indirect costs of care.4 5 9 10 
While ABR has predominantly been a clin-
ical problem in hospital settings, there is 
increasing evidence that resistant organisms 
are prevalent at the primary-care level.11 
A significant force driving the spread of 
ABR is the inappropriate use and prescription 
strengths and limitations of this study
 ► This study will focus on behaviour change interven-
tions, using the Behaviour Change Wheel to system-
atically classify interventions.
 ► Studies written in multiple languages (English, 
Spanish, French and Portuguese) will be considered.
 ► The GRADE checklist will be used to assess quality 
and strength of the evidence.
 ► Effectiveness and cost-effectiveness outcomes of 
the included data might be too heterogeneous to 
conduct a meta-analysis; if so, a narrative synthesis 
of evidence will be conducted.
 ► Studies may not report process and/or wider contex-
tual factors that could facilitate or act as a barrier to 
the success of an intervention.
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of antibiotics in primary care and hospital settings.7 12 
Low-income and middle-income countries (LMICs) are 
especially vulnerable, owing to a high burden of infec-
tious diseases and limited resources to treat them.13–15 A 
complex range of determinants of the inappropriate use of 
antibiotics has been identified in LMIC settings including 
lack of provider knowledge7 14 16–18; prescriber’s habit7 17 18; 
limited availability of independent, non-pharmaceutical 
industry sources of information about the effects of 
medicines17; lack of continuing medical education and 
supervision17 19–21; pharmaceutical promotion17 21; short 
doctor–patient–dispenser interaction time1 17; peer pres-
sure2 17 18 22 23; perceived and real patient demand17 18 24; 
lack of diagnostic support tools,1 17 economic incentives 
to prescribers and/or dispensers17 18 25; inappropriate 
medicine supply17 18 26; and how patients and community 
members use or consume prescribed medicines.18
Interventions to tackle these different determinants 
must be a key part of any strategy to address ABR.12 
Recently published systematic reviews have identified 
a range of interventions that could improve antibiotic 
stewardship.6 27–29 These interventions include the use 
of printed educational materials6 27; audit and feed-
back6 27; interactive educational meetings6 27; didactic 
lectures, compliance with antibiotic guidelines28; rein-
forcement of existing guidelines or their development, 
if previously non-existent28; and physician reminders 
to improve the prescription and use of antibiotics6 27 as 
means for improving the use and prescription of anti-
biotics. Another set of interventions uses mass media 
communication campaigns to reach both the public 
and prescribers through nationwide campaigns or 
more targeted interventions.29 The majority of studies 
included in these reviews used data from interventions 
implemented in high-income settings. Only 26 of the 221 
studies included in the review by Davey et al,27 4 of the 39 
studies included in the review by Arnold and Straus6 and 
1 of the 14 included studies in the review by Cross et al29 
were set in LMICs. The review by Charani et al28 did not 
include any interventions set in LMICs.
The studies included in all four reviews appraised 
both single and multi-faceted interventions. Overall, 
multi-faceted interventions (more than one intervention 
component) were more effective in the improvement of 
antibiotic use and prescribing.1 6 17 22 29 All studies included 
in these reviews were set in the health facilities (ambu-
latory and inpatient), and did not include any interven-
tions implemented in the community setting. Moreover, 
only two reviews included behaviour change interven-
tions.28 29 None of these reviews provided any estimates of 
costs of delivery or cost-effectiveness of the implemented 
interventions. This leaves a considerable knowledge gap 
for LMICs where resistance to antibiotics is growing at an 
alarming rate.16 25
The aim of this protocol is to provide a comprehen-
sive overview of the methods that will identify behaviour 
change interventions implemented in LMICs to improve 
the prescription and use of antibiotics, and appraise their 
effectiveness and cost-effectiveness through a system-
atic review of available evidence. The proposed review 
will summarise and critically appraise the evidence on 
behaviour change interventions implemented to improve 
the prescription and use of antibiotics in LMICs. Specifi-
cally, the objectives of the review are to:
1. Identify behaviour change interventions implement-
ed in LMICs to improve the prescription and use of 
antibiotics in inpatient and outpatient settings.
2. Synthesise the available evidence to determine the ef-
fectiveness and cost-effectiveness of the implemented 
behaviour change interventions, using the framework 
outlined by the Behaviour Change Wheel (BCW).30
3. Appraise the quality of the studies included in the re-
view using criteria set in the GRADE checklist.31
4. Identify the intervention components that are most 
strongly associated with effectiveness and cost-effec-
tiveness.
5. Identify knowledge gaps to guide future research 
in this area in the content of health promotion and 
health system interventions.
MEthOds
Population, interventions and outcomes
For the review, we will consider peer-reviewed and 
published studies that evaluate the effectiveness and 
cost-effectiveness of behaviour change interventions to 
improve the prescription and use of antibiotics in LMICs. 
We follow Michie et al’s definition of behaviour change—‘a 
coordinated set of activities designed to change specified 
behaviour patterns’ (p1).30 We will consider interventions 
targeting healthcare workers (including doctors, nurses, 
pharmacists and support staff), patients and community, 
and we will review all primary and secondary outcomes 
relating to antibiotic prescription and use.
Inclusion and exclusion criteria
Based on Michie et al’s BCW, we will include those 
interventions that focus on education, training, model-
ling, enablement, persuasion, incentivisation, coercion, 
restriction and environmental restructuring.30
The BCW is a layered framework (figure 1).30 At the 
centre of this framework is the capability, opportunity, 
motivation and behaviour (COM-B) model that recog-
nises that behaviour is part of an interacting system 
involving multiple components that include ‘capa-
bility’, ‘opportunity’, ‘motivation’ and ‘behaviour’. This 
allows for the investigation of a situation by defining 
the problem, specifying the target behaviour and iden-
tifying changes needed. The next circle contains the 
intervention functions such as training, enablement, 
education that might be necessary to address the gaps 
identified by the COM-B model. The outermost circle 
of the BCW is built on categories of policy that can 
potentially support the implementation and delivery of 
the intervention functions that are appropriate for the 
setting (figure 1).
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We will include studies that evaluate interventions 
within the framework of a randomised controlled trial 
(RCT), interrupted time series (ITS), controlled before–
after (CBA) or have a quasi-experimental design, as the 
experimental design allows rigorous testing and estab-
lishment of causal relationships, and the ruling out of 
alternative causes.32 We will include studies undertaken 
in countries classified as LMIC using the World Bank’s 
2016 country classification.33 The complete list of coun-
tries can be found in online supplementary appendix 
1. The review will comprise articles published between 
1990 and 2017, reflecting the period over which debate 
around appropriate use of antibiotics gained significant 
momentum.34
Studies written in languages other than those that 
the authors are proficient in (English, Spanish, French 
and Portuguese) will be excluded. Finally, we will also 
exclude conference abstracts, trial protocols, previous 
systematic reviews and non-peer reviewed publications of 
programme or intervention evaluation.
search strategy
The study team (NB, CC, MK and VW) will define the 
search terms to be used. These will be categorised into 
different domains, based on the research question 
(table 1). These domains are: population, interventions, 
outcomes and countries. The process will be iterative, as 
key search terms might change throughout the process. 
Two researchers from the review team (CC and NB) 
will independently conduct comprehensive searches for 
peer-reviewed articles using two online research data-
bases: Web of Science and PubMed. They will use the 
same set of keywords to search for studies in Google 
Scholar and screen the first 100 hits for peer-reviewed 
articles that might have been missed in the previous data-
base searches. They will hand-search the references of the 
final included studies to capture additional studies that fit 
the inclusion criteria.
data analysis and synthesis
The search results will be extracted into Mendeley 
V.1.17.11 and checked for duplicates which will be 
removed. CC and NB will independently screen all titles 
and abstracts retrieved from their literature searches. 
If there is uncertainty around whether certain studies 
should be included, the other team members (MK and 
VW) will independently appraise these studies to resolve 
the uncertainty. Following this screening phase, one 
researcher (CC) will review the full text of the papers 
to ensure that all inclusion criteria are met. Studies not 
meeting one or more of the inclusion criteria will be 
excluded. If there is uncertainty around the inclusion 
of studies at this stage, a second round of appraisal will 
be undertaken by MK. Any outstanding disputes will be 
resolved by VW. The selection process will be summarised 
in a flow chart that will also document the number of 
excluded studies and reasons for exclusion (figure 2). 
Studies published in Spanish, French or Portuguese will 
be translated by CC into English and made available for 
the team to discuss. CC will extract the data into a data 
extraction form in Excel to capture details about the 
authors, country setting, study design, description of 
intervention package, outcome indicators and results.
Once the data have been extracted, we will categorise 
studies according to the different types of behaviour 
change interventions using the BCW. Interventions will 
be assessed as either single or multi-faceted, as well as by 
the level of effectiveness and/or cost-effectiveness, and 
Figure 1 Behaviour Change Wheel (reproduced from Michie et al30).
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generalisability of results. Given that the included studies 
might have different evaluation designs, we will analyse the 
results for RCT, ITS, CBA and quasi-experimental studies 
separately. We anticipate a high degree of heterogeneity 
among study outcomes as interventions will be tailored 
to specific behaviours, populations and country settings. 
If there is some degree of homogeneity in the outcomes 
assessed across all or a subset of included studies, we will 
conduct a meta-analysis of effect with subgroup analysis. 
Otherwise, a narrative synthesis strategy will be used.35 
Careful consideration will also be given to publication 
bias across studies and selective reporting within studies.
Finally, we will conduct an appraisal of the quality of 
the included studies using the GRADE checklist31 which 
has been widely used by the WHO, Cochrane Collabora-
tion, Agency for Healthcare Research and Quality (USA) 
and National Institute for Health and Care Excellence 
(UK).36 This checklist explicitly evaluates the quality of 
the evidence and the strengths and weaknesses of the 
recommendations that follow.37
study dates
This study is ongoing, and the anticipated completion 
date for data extraction is 31 May 2018.
Patient and public involvement
Patients and/or public are not involved in this study.
Ethics and dissemination
As no individual patient data are used in this study, ethical 
approval is not required. The systematic review’s find-
ings will be disseminated in a peer-reviewed journal and 
presented at relevant international conferences.
dIsCussIOn
The extent of the adverse impacts of ABR is widely known 
and recognised as a global public health concern. Timely 
and appropriate interventions and programmes need 
to be implemented to alleviate its harmful impact on 
people, communities and health systems. This review will 
Table 1 Proposed keywords for systematic review search strategy
Population — 
drugs
antibiotic*; antimicrobial*; “anti-bacterial agents” ; antibacterial; anti-bacterial 
Interventions “behavioural intervention*”, “behavioral intervention*”, “behaviour intervention”, “behavior intervention”, 
“behaviour change”, “behavior change”, “behaviour modification”, “behavior modification”, “training”, 
“supervision”, “education”, “knowledge”, “feedback”, “audit”, “reminders”, “modelling”, “modeling”, 
“enablement”, “persuasion”, “incentivisation”, “incentivization’, “coercion”, “restriction”, “environmental 
restructuring”, “guidelines”, “stewardship”, “law enforcement”, “policy”, “governance”
Outcomes “use”, “rational use”, “irrational use”, “inappropriate use”, “appropriate use”, “appropriate treatment”, 
“treatment”, “prescription”, “adequate prescription”, “prescri*”, “knowledge”, “prophylactic use”, 
“prophilaxys”, “effectiveness”, “cost effectiveness”, “cost-effectiveness”, “economic evaluation”, “costs”, 
“costing”, “cost effectiveness analysis”, “cost-effectiveness analysis”, “cost benefit analysis”, “cost-
benefit analysis”, “cost utility analysis”, “cost-utility analysis”, “utilization”, “utilisation”, “drug use”, 
“medicine use”, “essential medicine*”, “drug information”, “drug therapy”, “consumption”, “prescribing 
practices”, “prescribing behaviour”, “prescribing behavior” 
Countries “low and middle income countr*”, “low income countr*”, “middle income countr*”, LMIC*, “developing 
countr*”, Afghanistan, Benin, Burkina Faso, Burundi, Central African Republic, Chad, Comoros, 
Democratic Republic of Congo, Eritrea, Ethiopia, The Gambia, Guinea, Guinea Bissau, Guinea-Bissau, 
Haiti, Democratic People's Republic of Korea, Korea, Liberia, Madagascar, Malawi, Mali, Mozambique, 
Nepal, Niger, Rwanda, Senegal, Sierra Leone, Somalia, South Sudan, Tanzania, Togo, Uganda, Zimbabwe, 
Armenia, Bangladesh, Bhutan, Bolivia, Cabo Verde, Cambodia, Cameroon, Republic of Congo, Congo, 
Cote d'Ivoire, Djibouti, Arab Republic of Egypt, Egypt, El Salvador, Ghana, Guatemala, Honduras, India, 
Indonesia, Kenya, Kiribati, Kosovo, Republic of Kyrgyz, Kyrgyz, Lao PDR, Lao, Lesotho, Mauritania, 
Federated States of Micronesia, Micronesia, Moldova, Mongolia, Morocco, Myanmar, Burma, Nicaragua, 
Nigeria, Pakistan, Papua New Guinea, Philippines, Samoa, Sao Tome and Principe, Solomon Islands, 
Sri Lanka, Sudan, Swaziland, Arab Republic of Syria, Syria, Tajikistan, Timor-Leste, Timor Leste, East 
Timor, Tonga, Tunisia, Ukraine, Uzbekistan, Vanuatu, Vietnam, West Bank and Gaza, Republic of Yemen, 
Yemen, Zambia, Albania, Algeria, American Samoa, Angola, Argentina, Azerbaijan, Belarus, Belize, Bosnia 
and Herzegovina, Botswana, Brazil, Bulgaria, China, Colombia, Costa Rica, Cuba, Dominica, Dominican 
Republic, Equatorial Guinea, Guinea, Ecuador, Fiji, Gabon, Georgia, Grenada, Guyana, Islamic Republic 
of Iran, Iran, Iraq, Jamaica, Jordan, Kazakhstan, Lebanon, Libya, Republic of Macedonia, Macedonia, 
Malaysia, Maldives, Marshall Islands, Mauritius, Mexico, Montenegro, Namibia, Palau, Panama, Paraguay, 
Peru, Romania, Russian Federation, Russia, Serbia, South Africa, St Lucia, St Vincent and the Grenadines, 
Suriname, Thailand, Turkey, Turkmenistan, Tuvalu, Venezuela RB, Venezuela
Terms within each row are separated by OR.
Terms across each row are separated by AND.
Limited to publications related to Humans.
Limited to publications from January 1990 to 2017.
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be one of the first to focus on interventions designed to 
improve the use of antibiotics in LMICs. The results will 
be of direct benefit to governments and donors who are 
seeking to respond to the threat of ABR by developing 
evidence-based national strategies and action plans that 
include priority interventions to control resistance to 
antibiotics and antimicrobials. This review will provide 
a comprehensive overview of available evidence on both 
the effectiveness and cost-effectiveness of interventions 
that will aid priority setting and investment decisions.
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